[go: up one dir, main page]

WO2008048902A8 - Methods of using single nucleotide polymorphisms in the il23r gene to predict or diagnose inflammatory bowel disease - Google Patents

Methods of using single nucleotide polymorphisms in the il23r gene to predict or diagnose inflammatory bowel disease Download PDF

Info

Publication number
WO2008048902A8
WO2008048902A8 PCT/US2007/081269 US2007081269W WO2008048902A8 WO 2008048902 A8 WO2008048902 A8 WO 2008048902A8 US 2007081269 W US2007081269 W US 2007081269W WO 2008048902 A8 WO2008048902 A8 WO 2008048902A8
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory bowel
risk
bowel disease
predict
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/081269
Other languages
French (fr)
Other versions
WO2008048902A3 (en
WO2008048902A2 (en
Inventor
Jerome I Rotter
Kent D Taylor
Stephan Targan
Richard H Duerr
Mark S Silverberg
Steven R Brant
John D Rioux
Judy H Cho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut de Cardiologie de Montreal
Mt Sinai Hospital
Yale University
Cedars Sinai Medical Center
Johns Hopkins University
University of Pittsburgh
Montreal Heart Inst
Original Assignee
Institut de Cardiologie de Montreal
Mt Sinai Hospital
Yale University
Cedars Sinai Medical Center
Johns Hopkins University
University of Pittsburgh
Montreal Heart Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut de Cardiologie de Montreal, Mt Sinai Hospital, Yale University, Cedars Sinai Medical Center, Johns Hopkins University, University of Pittsburgh, Montreal Heart Inst filed Critical Institut de Cardiologie de Montreal
Publication of WO2008048902A2 publication Critical patent/WO2008048902A2/en
Publication of WO2008048902A3 publication Critical patent/WO2008048902A3/en
Anticipated expiration legal-status Critical
Publication of WO2008048902A8 publication Critical patent/WO2008048902A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The inventors performed a genome-wide association study and identified interleukin-23 receptor (IL-23R) as an inflammatory bowel disease gene. Additionally, the inventors found both protective and risk allelic variants and haplotypes for Crohn's Disease. The inventors have also found that in non-Jewish individuals, risk haplotypes are associated with a higher median anti-I2 antibody level. The invention provides methods of identifying at-risk individuals and predicting disease course by determining the presence or absence in the individual of protective and risk variants in IL-23R.
PCT/US2007/081269 2006-10-13 2007-10-12 Methods of using single nucleotide polymorphisms in the il23r gene to predict or diagnose inflammatory bowel disease Ceased WO2008048902A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85147706P 2006-10-13 2006-10-13
US60/851,477 2006-10-13
US86310006P 2006-10-26 2006-10-26
US60/863,100 2006-10-26

Publications (3)

Publication Number Publication Date
WO2008048902A2 WO2008048902A2 (en) 2008-04-24
WO2008048902A3 WO2008048902A3 (en) 2008-12-24
WO2008048902A8 true WO2008048902A8 (en) 2009-07-30

Family

ID=39314760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/081269 Ceased WO2008048902A2 (en) 2006-10-13 2007-10-12 Methods of using single nucleotide polymorphisms in the il23r gene to predict or diagnose inflammatory bowel disease

Country Status (1)

Country Link
WO (1) WO2008048902A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
EP3639841B1 (en) 2013-03-27 2023-09-06 Cedars-Sinai Medical Center Treating fibrosis by inhibiting tl1a
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
JP7082945B2 (en) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター How to diagnose inflammatory bowel disease by RNASET2
WO2020087130A1 (en) * 2018-10-31 2020-05-07 The Council Of The Queensland Institute Of Medical Research Prognosis and treatment of inflammatory bowel disease

Also Published As

Publication number Publication date
WO2008048902A3 (en) 2008-12-24
WO2008048902A2 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
WO2008106579A3 (en) The role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
NZ591613A (en) Polymorphic marker rs965513 for risk assessment of thyroid cancer
NZ600235A (en) Methods and compositions for the assessment of drug response
NZ588037A (en) Serotonin transporter gene SLC6A4 and treatment of alcoholism
IL182519A0 (en) Methods and compositions for predicting drug responses
FI20050011A7 (en) Method and test kit for detecting the risk of type 2 diabetes mellitus
GB2477868A (en) Methods and systems for incorporating multiple environmental and genetic risk factors
Morgan et al. Genetic variation within TLR10 is associated with Crohn's disease in a New Zealand population
WO2008137762A3 (en) Methods of diagnosis and treatment of crohn's disease
WO2008067551A3 (en) Genetic analysis systems and methods
WO2009059321A3 (en) Rca locus analysis to assess susceptibility to amd and mpgnii
WO2008048986A3 (en) Gene array technique for predicting response in inflammatory bowel diseases
WO2008132763A3 (en) Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
WO2008017002A3 (en) Polymorphisms in genes affecting cns disorders and uses thereof
WO2008088893A3 (en) Gene polymorphisms in vegf and vegf receptor 2 as markers for cancer therapy
Sheng et al. Association analyses confirm five susceptibility loci for systemic lupus erythematosus in the Han Chinese population
WO2006069339A8 (en) Genetic variants of vkorci predicting warfarin sensitivity
WO2008048902A8 (en) Methods of using single nucleotide polymorphisms in the il23r gene to predict or diagnose inflammatory bowel disease
PL1730315T3 (en) Polymorphisms in nod2/card15 gene
WO2004108887A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2006123955A3 (en) Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms
WO2007002300A3 (en) Non-in situ hybridization method for detecting chromosomal abnormalities
Miranda et al. Association of angiotensin type 2 receptor gene polymorphisms with ureteropelvic junction obstruction in B razilian patients
WO2010014905A3 (en) Polymorphisms in the xbp-1 gene associated with inflammatory bowel disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07844239

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 07844239

Country of ref document: EP

Kind code of ref document: A2